120 related articles for article (PubMed ID: 35045497)
1. [A Case of Hyperammonemic Encephalopathy following mFOLFOX6 plus Panitumumab Therapy for Rectal Cancer].
Tsujio G; Muguruma K; Eguchi S; Iseki Y; Miki Y; Yoshii M; Fukuoka T; Tamura T; Shibutani M; Nagahara H; Toyokawa T; Tanaka H; Lee S; Yashiro M; Ohira M
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2073-2075. PubMed ID: 35045497
[TBL] [Abstract][Full Text] [Related]
2. [Considering Recurrence Prevention Regimen for Colorectal Cancer Patients with Hyperammonemia Caused by Chemotherapy Containing 5-Fluorouracil].
Aomatsu N; Tsujio G; Aomatsu K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1851-1853. PubMed ID: 38303229
[TBL] [Abstract][Full Text] [Related]
3. [A case of advanced rectal cancer treated with leucovorin, fluorouracil, and oxaliplatin plus panitumumab preoperative chemotherapy].
Takahashi H; Ishikawa T; Iwata N; Baba H; Masuda T; Okazaki S; Matsuyama T; Ishiguro M; Kobayashi H; Iida S; Uetake H; Sugihara K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1953-5. PubMed ID: 24393977
[TBL] [Abstract][Full Text] [Related]
4. A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.
Toritani K; Watanabe J; Suwa Y; Nakagawa K; Suwa H; Ishibe A; Ota M; Kunisaki C; Yamanaka T; Endo I
Int J Colorectal Dis; 2020 Dec; 35(12):2197-2204. PubMed ID: 32725346
[TBL] [Abstract][Full Text] [Related]
5. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Metastatic Colorectal Cancer with Hyperammonemic Encephalopathy Induced by mFOLFOX6 and SOX Therapy].
Murase H; Oono R; Yoshida T; Suzuki Y; Hayashi K; Nishino M; Irie T; Suzuki Y; Higuchi K; Baba H; Takahashi H; Yoshinouchi S; Ueda Y; Enjoji M; Obata M
Gan To Kagaku Ryoho; 2020 Dec; 47(13):1780-1782. PubMed ID: 33468827
[TBL] [Abstract][Full Text] [Related]
7. A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report.
Sonoda H; Shimizu T; Mekata E; Endo Y; Ishida M; Tani T
World J Surg Oncol; 2014 Mar; 12():63. PubMed ID: 24666666
[TBL] [Abstract][Full Text] [Related]
8. [Locally Advanced Rectal Cancer Presenting with Perforation That Was Successfully Resected after Preoperative Chemotherapy with mFOLFOX6 plus Panitumumab].
Sakabe R; Sakoda T; Yoshimura K; Murao N; Kuwada A; Tahara K; Hotei H; Maeda Y
Gan To Kagaku Ryoho; 2019 Mar; 46(3):475-477. PubMed ID: 30914588
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer].
Yoshino Y; Tamura A; Kagami S; Funahashi K
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1665-1668. PubMed ID: 30449860
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
Yukawa Y; Uchima Y; Kawamura M; Takeda O; Hanno H; Takayanagi S; Hirooka T; Dozaiku T; Hirooka T; Aomatsu N; Hirakawa T; Iwauchi T; Nishii T; Morimoto J; Nakazawa K; Takeuchi K
Gan To Kagaku Ryoho; 2016 May; 43(5):641-4. PubMed ID: 27210100
[TBL] [Abstract][Full Text] [Related]
11. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
[TBL] [Abstract][Full Text] [Related]
12. [A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy].
Nakano E; Kuroki M; Kanno N; Matsumura Y; Miura A; Kikuchi Y; Hirakawa H
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2581-4. PubMed ID: 24335375
[TBL] [Abstract][Full Text] [Related]
13. [Two cases of locally advanced colorectal cancer curatively resected after neoadjuvant chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin plus panitumumab].
Nakayasu Y; Yoshimatsu K; Yokomizo H; Osawa G; Yano Y; Nakayama M; Sakuma A; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Naritaka Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2029-31. PubMed ID: 24394002
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Severe Hyperammonemic Encephalopathy in a Dialysis Patient Following mFOLFOX6 Therapy].
Furuyama T; Enjoji M; Yamato M; Kondo I; Hinokida M; Tatsutomi Y; Nakazawa K; Nagayama K; Ushirokoji Y
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1676-1678. PubMed ID: 35046294
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH
Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684
[TBL] [Abstract][Full Text] [Related]
16. [Two Cases of Hepatic Encephalopathy after Chemotherapy for Metastatic Colorectal Cancer].
Matsumura T; Noura S; Hirota M; Ozato Y; Marukawa D; Shuto T; Muratsu A; Yasuyama A; Takata A; Koga C; Kameda C; Murakami M; Kawabata R; Shimizu J; Hasegawa J
Gan To Kagaku Ryoho; 2018 Apr; 45(4):694-696. PubMed ID: 29650838
[TBL] [Abstract][Full Text] [Related]
17. [Long-Term Effectiveness of Chemotherapy Containing mFOLFOX6 plus Panitumumab and 5-FU/l-LV plus Panitumumab after Primary Tumor Resection in a Case of Ascending Colon Carcinoma and Multiple Hepatic Metastases].
Kitahama T; Gomyo Y; Okada I; Akita N; Ikeno T; Miyamoto H
Gan To Kagaku Ryoho; 2019 Apr; 46(4):709-712. PubMed ID: 31164512
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
[TBL] [Abstract][Full Text] [Related]
19. Hyperammonemia-induced impaired consciousness following mFOLFOX6 therapy in a patient with recurrent rectal cancer.
Kurokawa T; Kanemoto Y; Azuma Y; Iimura Y; Kuroda S; Yazawa K; Tsurita G
Int J Clin Pharmacol Ther; 2021 Jun; 59(6):463-466. PubMed ID: 33860752
[TBL] [Abstract][Full Text] [Related]
20. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
